Abecma / Breyanzi / Carvykti / Kymriah / Tecartus / Yescarta - direct healthcare professional communication (DHPC)

idecabtagene vicleucel / Lisocabtagene maraleucel / tisagenlecleucel / brexucabtagene autoleucel / axicabtagene ciloleucel / ciltacabtagene autoleucel

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC) : Abecma, Breyanzi, Carvykti, Kymriah, Tecartus and Yescarta (CD19- or BCMA-directed CAR T-cell therapies): Risk of secondary malignancy of T-cell origin

Dissemination date: 18/07/2024

Key facts

• Medicine name:
  • Abecma
  • Breyanzi
  • Carvykti
  • Kymriah
  • Tecartus
  • Yescarta
• Active substance:
  • idecabtagene vicleucel
  • Lisocabtagene maraleucel
  • tisagenlecleucel
  • brexucabtagene autoleucel
  • axicabtagene ciloleucel
  • ciltacabtagene autoleucel
• Therapeutic area (MeSH):
  • Multiple Myeloma
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, Follicular
  • Mediastinal Neoplasms
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
  • Lymphoma, Mantle-Cell
• Regulatory outcome:
  Variation
• DHPC type:
  Adverse event
• Human ATC codes:
  • L01
  • L01XL05
  • L01XL04
  • L01X
  • L01XX70
• Dissemination date:
  18/07/2024